Literature DB >> 12695340

Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products.

Judy L Raucy1.   

Abstract

Human CYP3A4 metabolizes a majority of clinically important substrates at variable rates. Accounting for these unpredictable rates is the wide variation noted in expression of this enzyme that is due, in part, to xenobiotic exposure. We used primary cultures of human hepatocytes from 17 individuals to assess the inducibility of CYP3A4 mRNA by prototypical inducers, dietary flavonoids, and botanicals. Those agents producing the greatest mRNA accumulation were 10 microM RIF (699 +/- 307% of control levels) 100 microM phenytoin (707 +/- 188% of control), 1 mM phenobarbital (536 +/- 207% of control), and 100 microM omeprazole (404 +/- 8% of control). Various concentrations of RIF were found to exhibit a typical dose-response curve for CYP3A4 mRNA content. A reporter gene assay using the human pregnane X receptor (hPXR) and promoter regions of CYP3A4 transiently transfected into HepG2 cells, exhibited inductive properties by the aforementioned therapeutics that were similar to those observed in hepatocytes. Several flavonoids including quercetin, resveratrol, and curcumin were also examined for their ability to induce CYP3A4 in human hepatocytes. Only quercetin produced accumulation of CYP3A4 mRNA (230 +/- 73% of control). When examined in a reporter gene assay, this flavonoid exhibited negligible increases in luciferase activity suggesting that quercetin induced CYP3A4 by mechanisms that may not involve PXR. We also examined the effects of herbals on CYP3A4 expression in human hepatocytes. Grapeseed extract, ginseng, silymarin, and kava-kava produced 270 +/- 73, 155 +/- 83, 100 +/- 10, and 386 +/- 185% of control CYP3A4 mRNA, respectively. Of these botanicals only kava-kava produced enhanced luciferase activity (11.6 +/- 2.1 fold above DMSO treated cells). Such results indicate that kava-kava required PXR to mediate CYP3A4 induction. Collectively, results demonstrated that several botancials induce CYP3A4, suggesting the potential for drug-herbal interactions.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12695340     DOI: 10.1124/dmd.31.5.533

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  53 in total

1.  Pregnane X receptor-mediated induction of Cyp3a by black cohosh.

Authors:  Xiaoyan Pang; Jie Cheng; Kristopher W Krausz; De-an Guo; Frank J Gonzalez
Journal:  Xenobiotica       Date:  2010-10-27       Impact factor: 1.908

2.  A phase I/II trial and pharmacokinetic study of ixabepilone in adult patients with recurrent high-grade gliomas.

Authors:  David M Peereboom; Jeffrey G Supko; Kathryn A Carson; Tracy Batchelor; Surasak Phuphanich; Glenn Lesser; Tom Mikkelsen; Tom Mikkelson; Joy Fisher; Serena Desideri; Xiaoying He; Stuart A Grossman
Journal:  J Neurooncol       Date:  2010-05-07       Impact factor: 4.130

3.  Herbal product-drug interactions mediated by induction.

Authors:  Rommel G Tirona; David G Bailey
Journal:  Br J Clin Pharmacol       Date:  2006-06       Impact factor: 4.335

4.  Activation of CAR and PXR by Dietary, Environmental and Occupational Chemicals Alters Drug Metabolism, Intermediary Metabolism, and Cell Proliferation.

Authors:  J P Hernandez; L C Mota; W S Baldwin
Journal:  Curr Pharmacogenomics Person Med       Date:  2009-06-01

5.  Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: comparison of a milk thistle and black cohosh product to rifampin and clarithromycin.

Authors:  Bill Gurley; Martha A Hubbard; D Keith Williams; John Thaden; Yudong Tong; W Brooks Gentry; Philip Breen; Danielle J Carrier; Shreekar Cheboyina
Journal:  J Clin Pharmacol       Date:  2006-02       Impact factor: 3.126

6.  Statins and phenytoin interact - a case history.

Authors:  Kit Mun Tan; John G Kelly; Kathleen McGarry
Journal:  Br J Clin Pharmacol       Date:  2007-07-04       Impact factor: 4.335

Review 7.  Pharmacogenomics of CYP3A: considerations for HIV treatment.

Authors:  Sukhwinder S Lakhman; Qing Ma; Gene D Morse
Journal:  Pharmacogenomics       Date:  2009-08       Impact factor: 2.533

8.  Cryopreserved human hepatocytes as alternative in vitro model for cytochrome p450 induction studies.

Authors:  Martha Garcia; Joseph Rager; Qing Wang; Robert Strab; Ismael J Hidalgo; Albert Owen; Jibin Li
Journal:  In Vitro Cell Dev Biol Anim       Date:  2003 Jul-Aug       Impact factor: 2.416

9.  Relationship between the C3435T and G2677T(A) polymorphisms in the ABCB1 gene and P-glycoprotein expression in human liver.

Authors:  Andrew Owen; Chris Goldring; Paul Morgan; David Chadwick; B Kevin Park; Munir Pirmohamed
Journal:  Br J Clin Pharmacol       Date:  2005-03       Impact factor: 4.335

10.  Effect of phenytoin on celecoxib pharmacokinetics in patients with glioblastoma.

Authors:  Stuart A Grossman; Jeffrey Olson; Tracy Batchelor; David Peereboom; Glenn Lesser; Serena Desideri; Xiaobu Ye; Tarek Hammour; Jeffrey G Supko
Journal:  Neuro Oncol       Date:  2008-02-20       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.